LU91306I2 - Mitratapide, optionnellement sous forme d'un sel d'addition acide pharmaceutiquement acceptable (YARVITAN) - Google Patents

Mitratapide, optionnellement sous forme d'un sel d'addition acide pharmaceutiquement acceptable (YARVITAN)

Info

Publication number
LU91306I2
LU91306I2 LU91306C LU91306C LU91306I2 LU 91306 I2 LU91306 I2 LU 91306I2 LU 91306 C LU91306 C LU 91306C LU 91306 C LU91306 C LU 91306C LU 91306 I2 LU91306 I2 LU 91306I2
Authority
LU
Luxembourg
Prior art keywords
yarvitan
mitratapide
optionally
pharmaceutically acceptable
acid addition
Prior art date
Application number
LU91306C
Other languages
English (en)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/455,304 external-priority patent/US5521186A/en
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of LU91306I2 publication Critical patent/LU91306I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
LU91306C 1994-10-27 2007-01-17 Mitratapide, optionnellement sous forme d'un sel d'addition acide pharmaceutiquement acceptable (YARVITAN) LU91306I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP94203120 1994-10-27
US08/455,304 US5521186A (en) 1994-10-27 1995-05-31 Apolipoprotein-β synthesis inhibitors
PCT/EP1995/004111 WO1996013499A1 (fr) 1994-10-27 1995-10-19 Inhibiteurs de synthese d'apolipoproteines-b

Publications (1)

Publication Number Publication Date
LU91306I2 true LU91306I2 (fr) 2007-03-19

Family

ID=26136684

Family Applications (1)

Application Number Title Priority Date Filing Date
LU91306C LU91306I2 (fr) 1994-10-27 2007-01-17 Mitratapide, optionnellement sous forme d'un sel d'addition acide pharmaceutiquement acceptable (YARVITAN)

Country Status (30)

Country Link
US (1) US5929075A (fr)
EP (1) EP0788496B1 (fr)
JP (1) JP3025907B2 (fr)
KR (1) KR100227231B1 (fr)
CN (1) CN1068000C (fr)
AP (1) AP779A (fr)
AT (1) ATE198889T1 (fr)
AU (1) AU697744C (fr)
BG (1) BG63694B1 (fr)
BR (1) BR9509436A (fr)
CA (1) CA2203274C (fr)
CY (1) CY2256B1 (fr)
CZ (1) CZ286476B6 (fr)
DE (3) DE122007000005I2 (fr)
DK (1) DK0788496T3 (fr)
ES (1) ES2155535T3 (fr)
FI (1) FI119548B (fr)
GR (1) GR3035519T3 (fr)
HR (1) HRP950532B1 (fr)
HU (1) HU219862B (fr)
IL (1) IL115771A (fr)
LU (1) LU91306I2 (fr)
NO (1) NO311937B1 (fr)
NZ (1) NZ295353A (fr)
OA (1) OA10479A (fr)
PT (1) PT788496E (fr)
RO (1) RO118715B1 (fr)
SK (1) SK281908B6 (fr)
TR (1) TR199501295A2 (fr)
WO (1) WO1996013499A1 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6342245B1 (en) * 1997-11-03 2002-01-29 Janssen Pharmaceutica N.V. Compositions of lipid lowering agents
CA2328970A1 (fr) * 1998-04-27 1999-11-04 Valentin Florent Victor De Conde Comprimes comportant un noyau enrobe par un agent reducteur de lipides et par un polymere
NZ512891A (en) * 1998-12-22 2003-01-31 Janssen Pharmaceutica Nv S-oxide lipid lowering compounds
DE19945982A1 (de) * 1999-09-24 2001-03-29 Knoll Ag Geschwindigkeitsbestimmte Partikel
US20050132022A1 (en) * 2003-12-12 2005-06-16 International Business Machines Corporation Computer system with LAN-based I/O
CA2552988A1 (fr) * 2004-01-21 2005-08-04 Janssen Pharmaceutica Nv Solution orale de mitratapide
US7649002B2 (en) 2004-02-04 2010-01-19 Pfizer Inc (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
CA2562015A1 (fr) * 2004-04-09 2005-10-20 Janssen Pharmaceutica Nv Schema posologique intermittent destine a des sujets obeses ou en surpoids
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
CA2609783A1 (fr) * 2005-05-27 2006-12-07 Pfizer Products Inc. Polytherapie pour le traitement de l'obesite ou le maintien du poids apres une perte ponderale
US20080269233A1 (en) * 2005-08-04 2008-10-30 Mark David Andrews Piperidinoyl-Pyrrolidine and Piperidinoyl-Piperidine Compounds
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
ES2402581T3 (es) * 2006-02-23 2013-05-06 Pfizer Limited Piperidinoilpirrolidinas como agonistas del receptor de melanocortina tipo 4
US8383660B2 (en) 2006-03-10 2013-02-26 Pfizer Inc. Dibenzyl amine compounds and derivatives
CN101583593A (zh) 2006-11-13 2009-11-18 辉瑞产品公司 二芳基、二吡啶基和芳基-吡啶基衍生物及其用途
WO2008070496A2 (fr) 2006-12-01 2008-06-12 Bristol-Myers Squibb Company Inhibiteurs d'amino cetp étendus
WO2008145605A1 (fr) 2007-05-25 2008-12-04 Janssen Pharmaceutica Nv Synthèse perfectionnée de méthanesulfonate de (2s-cis)-2-(bromométhyl)-2-(4-chlorophényl)-1,3 dioxolane-4-méthanol(ester)
MX2011001405A (es) * 2008-08-06 2011-03-21 Pfizer Ltd Compuestos de diazepina y diazocano como agonistas de mc4.
BR112012029227B1 (pt) * 2010-05-19 2020-01-07 Sandoz Ag Processo para a preparação de um composto quiral, composto quiral e uso de um composto
PE20251292A1 (es) 2018-03-08 2025-05-14 Incyte Corp Compuestos diolicos de aminopirazina como inhibidores de pi3k-gamma
WO2020010003A1 (fr) 2018-07-02 2020-01-09 Incyte Corporation DÉRIVÉS D'AMINOPYRAZINE UTILISÉS EN TANT QU'INHIBITEURS DE PI3K-γ

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4267179A (en) * 1978-06-23 1981-05-12 Janssen Pharmaceutica, N.V. Heterocyclic derivatives of (4-phenylpiperazin-1-yl-aryloxymethyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles
US4313953A (en) * 1978-06-23 1982-02-02 Janssen Pharmaceutica, N.V. Heterocyclic derivatives of (4-aryloxymethyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles
US4766125A (en) * 1981-06-23 1988-08-23 Janssen Pharmaceutica N.V. N-aryl-piperazinealkanamides useful for protecting hearts from myocardial injury caused by ischaemia, anoxia or hypoxia
US4619931A (en) * 1983-02-28 1986-10-28 Janssen Pharmaceutica, N.V. [[4-[4-(4-phenyl-1-piperazinyl)phenoxymethyl]-1,3-dioxolan-2-yl]methyl]-1H-imidazoles and 1H-1,2,4-triazoles
CA1292472C (fr) * 1985-12-03 1991-11-26 Alfonsus Guilielmus Knaeps Derives des ({4-¬4-(4-phenyl-1-piperazinyl)-phenoxymethyl|- 1,3-dioxolan-2-yl}methyl)-1h-imidazoles et 1h-1,2,4-triazoles
NZ223799A (en) * 1987-03-25 1989-12-21 Janssen Pharmaceutica Nv Azolylmethyl-dioxolanylmethoxyphenyl-piperazinyl-phenyl-triazolones and antimicrobial compositions
CA1331757C (fr) * 1988-02-29 1994-08-30 Janssen Pharmaceutica Naamloze Vennootschap 5-lipoxygenase inhibant les 4-(4-phenyl-1-piperazinyl)phenols
WO1994020063A2 (fr) * 1993-03-04 1994-09-15 Cytoven International N.V. Tryptophane pharmaceutique contenant des compositions dipeptidiques et modes d'utilisation
US5521186A (en) * 1994-10-27 1996-05-28 Janssen Pharmaceutica N.V. Apolipoprotein-β synthesis inhibitors

Also Published As

Publication number Publication date
KR100227231B1 (ko) 1999-11-01
FI971784L (fi) 1997-04-25
CZ119897A3 (cs) 1998-03-18
DE69519995D1 (en) 2001-03-01
US5929075A (en) 1999-07-27
NZ295353A (en) 1998-08-26
CA2203274A1 (fr) 1996-05-09
CZ286476B6 (en) 2000-04-12
AP779A (en) 1999-11-03
OA10479A (en) 2002-04-09
CN1161695A (zh) 1997-10-08
JP3025907B2 (ja) 2000-03-27
IL115771A0 (en) 1996-01-19
NO311937B1 (no) 2002-02-18
BR9509436A (pt) 1998-01-06
HU219862B (hu) 2001-08-28
IL115771A (en) 2000-02-29
DE122007000005I1 (de) 2007-04-26
ATE198889T1 (de) 2001-02-15
SK50797A3 (en) 1998-04-08
FI119548B (fi) 2008-12-31
HUT77360A (hu) 1998-03-30
CA2203274C (fr) 2002-02-19
AP9700968A0 (en) 1997-04-30
BG101402A (en) 1997-10-31
EP0788496B1 (fr) 2001-01-24
RO118715B1 (ro) 2003-09-30
DE122007000005I2 (de) 2008-04-24
EP0788496A1 (fr) 1997-08-13
CN1068000C (zh) 2001-07-04
ES2155535T3 (es) 2001-05-16
HRP950532A2 (en) 1997-08-31
FI971784A0 (fi) 1997-04-25
NO971895L (no) 1997-04-24
WO1996013499A1 (fr) 1996-05-09
AU697744C (en) 2002-08-22
DK0788496T3 (da) 2001-06-18
BG63694B1 (bg) 2002-09-30
NO971895D0 (no) 1997-04-24
AU3868095A (en) 1996-05-23
GR3035519T3 (en) 2001-06-29
MX9703074A (es) 1997-07-31
CY2256B1 (en) 2003-07-04
SK281908B6 (sk) 2001-09-11
JPH09511759A (ja) 1997-11-25
PT788496E (pt) 2001-07-31
HRP950532B1 (en) 2001-06-30
DE69519995T2 (de) 2001-08-23
AU697744B2 (en) 1998-10-15
TR199501295A2 (tr) 1996-06-21

Similar Documents

Publication Publication Date Title
LU91306I2 (fr) Mitratapide, optionnellement sous forme d'un sel d'addition acide pharmaceutiquement acceptable (YARVITAN)
LU88809I2 (fr) Lamivudine facultativement sous la forme d'un sel pharmaceutiquement acceptable
LU91442I2 (fr) "Varénicline, optionnellement sous forme d'un sel pharmaceutiquement acceptable, y compris le sel tartrate"
LU91372I2 (fr) Retapamulin optionnellement sous forme d'un sel pharmaceutiquement acceptable (altargo)
LU88746I2 (fr) Valaciclovir facultativement sous la forme d'un sel pharmaceutiquement acceptable y compris le sel d'addition de l'acide chlorhydrique
LU90593I2 (fr) Quetiapine facutativement sous forme d'un sel pharmaceutiquement acceptabe
LU92428I2 (fr) Bosutinib, éventuellement sous la forme d'un sel pharmaceutiquement acceptable
LU92407I2 (fr) Afatinib, éventuellement sous la forme d'un sel pharmaceutiquement acceptable, y compris le sel dimaléate
LU91290I2 (fr) Céfovécine, optionnellement sous la forme d'un sel, dont le sel de sodium (CONVENIAr)
LU88842I2 (fr) Nebivolol optionnellement sous forme d'un sel ou d'un hydrate pharmaceutiquement acceptable en particulier hydroclorure de Nebivolol
LU90426I2 (fr) Abacavir facultativement sous la forme d'un sel pharmaceutiquement acceptable ou d'un d-rive y compris le sulfate d'abacavir
LU91599I2 (fr) Lasofoxifene, optionnellement sous forme d'un sel d'addition acide, d'un N-oxyde, d'unester ou d'un sel d'ammonium quaternaire, non toxiques et pharmacologiquement acceptables, y compris le sel tartrate (FABLYN - lasofoxifene)
LU90468I2 (fr) Zanamivir facultativement sous la forme d'un sel ou d'un derive pharmaceutiquement acceptable
LU91181I2 (fr) Ziconotide, optionnellement sous forme d'un sel avec un acide pharmaceutiquement acceptable, y compris acetate de ziconotide (prialt).
LU92699I2 (fr) Bazédoxifène, éventuellement sous la forme d'un sel pharmaceutiquement, acceptable tel que le sel d'acétate, et d'estrogènes conjugués
LU91027I2 (fr) Dutasteride optionnellement sous forme d'un solvate pharmaceutiquement acceptable
LU90234I2 (fr) Une combination comprenant de la lamivudine facultativement sous la forme d'un sel pharmaceutiquement acceptable et de la zidovudine
NO2010003I1 (no) Prukaloprid eller et farmasøytisk aksepterbart syreaddisjonssalt derav
LU91681I2 (fr) "Eltrombopag,éventuellement sous forme d'un sel oud'un solvate (y compris sous forme d'un hydrate) pharmaceutiquement acceptable (REVOLADE)"
LU92397I2 (fr) Vortioxétine ou un sel d'addition d'acide de celui-ci pharmaceutiquement acceptable
FI925342L (fi) Menetelmä terapeuttisesti aktiivisen (+)- -(2,3-dimetoksifenyyli)-1-/2-(4-fluorifenyyli)etyyli/-4-piperidiinimetanolin valmistamiseksi
EP1574219A3 (fr) Procédé d'inhibition de la fibrose avec un agoniste de la somatostatine
GB0117095D0 (en) "Process for the preparation of pure citalopram"
LV5765B4 (lv) (S)-(-)-1-propil-2',6'-pipekoloksilidida hidrohlorida monohidrats ta iegusanas metode un to satuross farmaceitisks preparats
IT8919737A0 (it) Impiego di 5' metiltioadenosina, s adenosilmetionina e dei loro sali per la preparazione di composizioni farmaceutiche atte a ridurre la seborrea e composizioni farmaceutiche relative.